Sustained release of a highly specific GSK3β inhibitor SB216763 in the PCL scaffold creates an osteogenic niche for osteogenesis, anti-adipogenesis, and potential angiogenesis

The safe and effective use of Wnt signaling is a hot topic in developing osteogenic drugs. SB216763 (S33) is a widely used highly specific GSK3β inhibitor. Here, we show that S33 initiates canonical Wnt signaling by inhibiting GSK3β activity in the bone marrow stromal cell line ST2 and increases ost...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Weimin, Li, Molin, Zhao, Lizhou, Wang, Pengtao, Wang, Xiaofang, Wang, Bo, Liu, Xing, Tu, Xiaolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Bioengineering and Biotechnology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419179/
https://www.ncbi.nlm.nih.gov/pubmed/37576993
http://dx.doi.org/10.3389/fbioe.2023.1215233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419179/
https://www.ncbi.nlm.nih.gov/pubmed/37576993
http://dx.doi.org/10.3389/fbioe.2023.1215233

Ejemplares similares